Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
Altered serum levels of nicotinamide phosphoribosyltransferase, omentin-1, and caspase-cleaved cytokeratin 18 fragment M30 in children with type 1 diabetes may signify metabolic differences that do not stabilize with insulin treatment.
Repeated exposure to high levels of HbA1c was associated with increased risk for dementia in a cohort of patients age ≥50 with type 1 diabetes.
Individuals with higher executive function performance at baseline experienced slower increases in HbA1c.